Complete response in myeloma: A Trojan horse?

Blood

Volumn 108, Issue 7, 2006, Pages 2134-

  Barlogie, Bart ^a   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; MELPHALAN; THALIDOMIDE;

AUTOTRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; HIGH RISK PATIENT; HUMAN; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33749327635     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-034538     Document Type: Note

References (10)

1. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
4. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825-831.
5. Facon T, Mary J, Harousseau J, et al. on behalf of the Intergroupe Francophone du Myelome, A. Peny. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple Myeloma [abstract]. J Clin Oncol. 2006;24:18S.
6. Fassas A, Rasmussen E, Shaughnessy J, et al. Complete response (CR) with total therapy 2 (TT2) for multiple myeloma (MM): low frequency in case of prior MGUS without adverse consequences for survival - yet critical for disease control in presumed "de novo" MM [abstract]. Blood. 2005;106:342a. Abstract 1172.
7. Barlogie B, Tricot G, van Rhee F, et al. Long term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. In press.
8. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and post-transplantation consolidation therapies. Blood. 2006;107:2633-2683.
9. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
10. Walker R, Jones-Jackson L, Rasmussen E, et al. MRI-detectable focal lesions (FL) in multiple myeloma (MM) at relapse frequently involve novel sites not involved at diagnosis [abstract]. Blood. 2004;104:364b. Abstract 5124.